Back to results
US 7,351,429 B1Granted
Oral solid preparation
AssigneeKyorin Pharmaceutical Co., Ltd.
InventorsToshinori Ohyama, Masahiko Ohishi, Yasuhiro Yamamoto
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeKyorin Pharmaceutical Co., Ltd.
InventorsToshinori Ohyama, Masahiko Ohishi, Yasuhiro Yamamoto
Estimating the term…
The invention is to provide an oral solid pharmaceutical that is uniform in the content of KRP-197, having bladder-selective anticholinergic activity, being a therapeutic drug for pollakiuria and urinary incontinence, and being active with a very low dosage, that can be taken quantitatively, and that is easy in the handling. Since KRP-197 becomes unstable to light under the influence of additives, the invention is to select the additives to be used and to obtain a pharmaceutical with high stability. By formulating KRP-197 with drug-making carriers, a pharmaceutical that is uniform in the content, capable of taking quantitatively and easy in the handling has been provided. Furthermore, by using polyvinyl pyrrolidone for binder and by making into tablet coated with a coating base containing titanium dioxide and ferric oxide, a pharmaceutical capable of taking quantitatively and excellent in the light stability has been provided.
An oral solid pharmaceutical in tablet form comprising 0.025 to 2 mg of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as an active ingredient, excipient, binder, lubricant and coating agent, which is obtained by spraying a solution of the active ingredient and the binder on the excipient, granulating and then drying the resultant mixture, pressing the granulated and dried mixture to give a plane tablet in the presence of the lubricant, and then coating the plane tablet with the coating agent to give a coated tablet, wherein the coating agent comprises titanium dioxide and ferric oxide in an mg-equivalent ratio of between 43:7 and 52:8.
Dependencies are inferred from the claim text.